Misonix, Inc. (NASDAQ:MSON) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 265,700 shares, a growth of 33.9% from the May 30th total of 198,500 shares. Currently, 3.4% of the company’s shares are short sold. Based on an average daily volume of 62,300 shares, the short-interest ratio is presently 4.3 days.
Large investors have recently bought and sold shares of the stock. Rathbone Brothers plc raised its position in Misonix by 6.2% during the first quarter. Rathbone Brothers plc now owns 15,500 shares of the medical equipment provider’s stock valued at $298,000 after buying an additional 900 shares during the period. Tibra Equities Europe Ltd acquired a new position in Misonix during the first quarter valued at $327,000. Acadian Asset Management LLC raised its position in Misonix by 95.3% during the first quarter. Acadian Asset Management LLC now owns 18,558 shares of the medical equipment provider’s stock valued at $357,000 after buying an additional 9,054 shares during the period. Finally, Geode Capital Management LLC raised its position in Misonix by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 35,095 shares of the medical equipment provider’s stock valued at $561,000 after buying an additional 1,775 shares during the period. 21.17% of the stock is currently owned by hedge funds and other institutional investors.
MSON has been the topic of a number of recent analyst reports. TheStreet lowered Misonix from a “c-” rating to a “d” rating in a research report on Thursday, June 20th. BTIG Research initiated coverage on Misonix in a research report on Wednesday, June 12th. They set a “buy” rating and a $29.00 target price on the stock. Finally, BidaskClub raised Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.00.
Misonix (NASDAQ:MSON) last posted its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. The firm had revenue of $9.56 million for the quarter. Misonix had a negative return on equity of 29.13% and a negative net margin of 18.10%.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.